Instil Bio, Inc. (TIL) shares tumbled 45.97 percent on heavy trading, falling $5.65 to$6.64 on Tuesday, after the company announced the discontinuation of clinical development for AXN-2510 and the termination of its license and collaboration agreement with ImmuneOnco Biopharmaceuticals for AXN-2510 and AXN-27M. The biotech company said its wholly owned subsidiary, Axion Bio, decided to halt development of AXN-2510, leading to the termination agreement with ImmuneOnco. The news triggered sharp selling pres ...